American Journal of Cardiology
Volume 104, Issue 12 , Pages 1695-1696 , 15 December 2009

Optimal Management of Persistent Mixed Dyslipidemia After Statin Initiation Warrants Combination Therapy

  • William E. Boden, MD

      Affiliations

    • Department of Medicine, Division of Cardiovascular Medicine, State University of New York at Buffalo and Buffalo General Hospital, Buffalo, New York
    • Corresponding Author InformationCorresponding author: Tel: 716-859-2978; fax: 716-859-3949
    • ,
  • Mark E. McGovern, MD

      Affiliations

    • Miami, Florida

Received 3 August 2009 ,Revised 4 August 2009 ,Accepted 4 August 2009.

References 

  1. Nichols GA, Ambegaonkar BM, Sazonov V, Brown JB. Frequency of obtaining National Cholesterol Education Program Adult Treatment Panel III goals for all major serum lipoproteins after initiation of lipid altering therapy. Am J Cardiol. 2009;104:1689–1694
  2. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  3. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  4. Rubins HB, Robins SJ, Collins D, Iranmanesh A, Wilt TJ, Mann D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol. 1995;75:1196–1201
  5. Vittone F, Chait A, Morse JS, Fish B, Brown BG, Zhao XQ. Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: a subgroup analysis of the HDL-Atherosclerosis Treatment Study. J Clin Lipidol. 2007;1:203–210
  6. Ghanderhari H, Karnal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J. 2008;156:112–119
  7. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  8. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592
  9. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–3517
  10. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99(suppl):21I–33I
  11. Niacin plus statin to prevent vascular events. http://clinicaltrials.gov/ct2/show/NCT00120289?term=NCT00120289&rank=1Accessed August 25, 2009
  12. Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE). http://clinicaltrials.gov/ct2/show/NCT00461630?term=NCT00461630&rank=1Accessed August 25, 2009

PII: S0002-9149(09)01482-9

doi: 10.1016/j.amjcard.2009.08.003

American Journal of Cardiology
Volume 104, Issue 12 , Pages 1695-1696 , 15 December 2009

Article Tools